Arbutus Biopharma (ABUS) Q3 2024 Earnings Report

In the third quarter of 2024, Arbutus Biopharma Corporation reported revenues of $1.34 million, a significant decline of 71.25% year-over-year and 22.42% quarter-over-quarter. The extended cash burn demonstrates the company's commitment to advancing its R&D, focusing heavily on its HBV product pipeline, including the RNAi therapeutic imdusiran, which is preparing for a Phase IIb clinical trial. Management emphasized the importance of achieving a functional cure for chronic HBV, which continues to be a major health challenge globally. With cash reserves sufficient to sustain operations into the fourth quarter of 2026, Arbutus is positioned to capitalize on its innovative clinical programs despite the current financial strain.